Histopathology of pulmonary hypertension

Chest

Volumn 114, Issue 1 SUPPL., 1998, Pages 1S-6S

  Tuder, Rubin M ^a   Lee, Sang Do ^a   Cool, Carlyne C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE; PROSTACYCLIN SYNTHASE; THROMBOMODULIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

BLOOD VESSEL TONE; CONFERENCE PAPER; HUMAN; MEDIATOR RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOOTH MUSCLE CONTRACTION; VASCULAR SMOOTH MUSCLE; VASCULITIS;

EID: 0031830047     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.1_Supplement.1S-a     Document Type: Conference Paper

References (16)

1. Tuder RM, Groves B, Badesch DB, et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144:275-85
2. Yu S-M, Hung L-M, Lin C-C. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997; 95:1269-77
3. Tuder RM, Wang J, Lee SD, et al. Vascular endothelial growth factor (VEGF) expression in normal and remodeled pulmonary arteries in severe pulmonary hypertension. Am J Respir Crit Care Med 1997; 155:A627
4. Cool CD, Kennedy D, Voelkel NF, et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28:434-42
5. Tuder RM, Cool C, Jennings C, et al. Pulmonary vascular involvement in interstitial lung disease (ILD). In: Schwartz MI, King TE, eds. Interstitial lung disease. 3rd ed. New York: Mosby Year Book (in press)
6. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-39
7. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Am J Pathol 1994; 114: 286-95
8. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-21
9. Tuder RM, Wang J, Cool CD, et al. Prostacyclin synthase expression is decreased in lungs with severe pulmonary hypertension. Am J Respir Crit Care Med 1997; 155:A627
10. Vogelstein B, Fearon ER, Hamilton SR, et al. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 1985; 227:642-45
11. Lee S-D, Shroyer KR, Markham NE, et al. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101:927-34
12. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FIAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157:219-29
13. Lepley RA, Fitzpatrick FA. 5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J Biol Chem 1994; 269:24163-68
14. Christman BW, McPherson CD, Newman JH. An imbalance between the excretion of the thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-75
15. Hoeper MM, Thomas OB, Horan M, et al. The prostacyclin-analogue iloprost induces vascular endothelial growth factor in a human monocytic cell line and in rat lungs via a cAMP-dependent mechanism. Am J Respir Cell Mol Biol 1997;17:748-56
16. Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med 1997; 336:988-93